Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Metrics to compare | MGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMGXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −3.4x | −0.5x | |
PEG Ratio | −0.01 | −0.19 | 0.00 | |
Price/Book | 0.4x | 2.5x | 2.6x | |
Price / LTM Sales | 1.9x | 11.5x | 3.3x | |
Upside (Analyst Target) | 334.8% | 112.6% | 43.5% | |
Fair Value Upside | Unlock | 1.7% | 6.3% | Unlock |